<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Hoekstra, H.J.</title>
    <link>http://repub.eur.nl/res/aut/7550/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Betere navolging van de richtlijn 'melanoom' (Article)</title>
      <link>http://repub.eur.nl/res/pub/19315/</link>
      <pubDate>2010-01-01T00:00:00Z</pubDate>
      <description>Doel: Evaluatie van de mate waarin de in 2005 herziene behandelingsrichtlijn voor het melanoom werd gevolgd en de aandachtspunten van de vorige richtlijnevaluatie (in 2001) werden geïmplementeerd.
Opzet &amp; Methode: Retrospectief observationeel cohortonderzoek. De evaluatie werd uitgevoerd met gegevens uit de pathologieverslagen van patiënten die in de periode 1 april-30 september 2007 gediagnosticeerd werden met een melanoom van de huid in de ziekenhuizen in de regio’s van
het Integraal Kankercentrum Zuid (IKZ) en het Integraal Kankercentrum West (IKW).
Resultaten: Voor 85% van de patiënten werd het melanoom conform de richtlijn in twee sessies behandeld met een diagnostische excisie gevolgd door een therapeutische re-excisie. Voor melanoma in situ was dit cijfer 69% en voor invasief melanoom 87%; de andere patiënten werden in één sessie behandeld. In de pathologieverslagen van de patiënten met een invasief melanoom werd de marge van de diagnostische excisie voor 64%, de breslow-dikte voor 97% en de aan- of afwezigheid van ulceratie voor 77% vastgelegd. In de IKW-regio werd de marge van re-excisie nagegaan: bij 86% van de patiënten met een invasief melanoom voldeed deze marge aan de richtlijn.
Conclusie: Ten opzichte van de vorige richtlijnevaluatie in 2001 was het excisiebeleid verbeterd. Verbetering van de rapportage van de excisiemarge en van de aan- of afwezigheid van ulceratie in het pathologieverslag verdient aanbeveling.</description>
    </item> <item>
      <title>The power of the spoken word: Political mobilization and nation-building by Kuyper and Gladstone [De kracht van het gesproken woord. Politieke mobilisatie en natievorming bij Kuyper en Gladstone] (Article)</title>
      <link>http://repub.eur.nl/res/pub/15401/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>This article addresses the question why in the Netherlands it was the orthodox protestants who were able to mobilize the masses and not, the political establishment of liberals and enlightened protestants during the latter part of the nineteenth century. The biblical rhetoric of their leader Abraham Kuyper reflects the lack of a tradition of popular political participation until late in the nineteenth century in the Netherlands. In contrast, the liberal language of his Victorian counterpart Gladstone, whose evangelical creed was equally orthodox, was marked by the absence of biblical drama. The familiarity of the masses with the moral rationalism of political liberalism is related to a longer tradition of political participation and agitation among working men and the power of popular liberalism in general, in England during the nineteenth century.</description>
    </item> <item>
      <title>Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience (Article)</title>
      <link>http://repub.eur.nl/res/pub/8640/</link>
      <pubDate>1996-01-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: The objective of the study was to achieve limb salvage in
          patients with locally advanced soft tissue sarcomas that can only be
          treated by amputation or functionally mutilating surgery by performing an
          isolated limb perfusion (ILP) with tumor necrosis factor (TNF) + melphalan
          (M) as induction biochemotherapy to obtain local control and make
          limb-sparing surgery possible. SUMMARY BACKGROUND DATA: To increase the
          number of limb-sparing resections in the treatment of locally advanced
          extremity soft tissue sarcoma, preoperative radiation therapy or
          chemotherapy or a combination of the two often are applied. The ILP with
          cytostatic agents alone is another option but rarely is used because of
          rather poor results. The efficacy of the application of TNF in ILP
          markedly has changed this situation. METHODS: In 8 cancer centers, 186
          patients were treated over a period of almost 4.5 years. There were 107
          (57%) primary and 79 (43%) recurrent sarcomas, mostly high grade (110
          grade III; 51 grade II; and 25 very large, recurrent, or multiple grade I
          sarcomas). The composition of this series of patients is unusual: 42
          patients (23%) had multifocal primary or multiple recurrent tumors; median
          tumor size was very large (16 cm); 25 patients (13%) had known systemic
          metastases at the time of the ILP. Patients underwent a 90-minute ILP at
          39 to 40 C with TNF + melphalan. The first 55 patients also received
          interferon-tau. A delayed marginal resection of the tumor remnant was done
          2 to 4 months after ILP. RESULTS: A major tumor response was seen in 82%
          of the patients rendering these large sarcomas resectable in most cases.
          Clinical response rates were: 33 complete response (CR) (18%), 106 partial
          response (PR) (57%), 42 no change (NC) (22%), and 5 progressive disease
          (PD) (3%). Final outcome was defined by clinical and pathologic response:
          54 CR (29%), 99 PR (53%), 29 NC (16%), and 4 PD (2%). At a median
          follow-up of almost 2 years (22 months; range, 6-58 months), limb salvage
          was achieved in 82%. Regional toxicity was limited and systemic toxicity
          minimal to moderate, easily managed, with no toxic deaths. CONCLUSIONS: In
          the setting of isolated limb perfusion, TNF is an active anticancer drug
          in patients. The ILP with TNF + melphalan can be performed safely in many
          centers and is an effective induction treatment with a high response rate
          that can achieve limb salvage in patients with locally advanced extremity
          soft tissue sarcoma.</description>
    </item>
  </channel>
</rss>